Italy’s Little-Known Early Access Program
Italy’s early access system is mainly used for unapproved uses of authorized medicines, and is driven by clinicians, rather than companies.
You may also be interested in...
In the latest in a string of knockbacks for both Novartis and Roche, the EU’s highest court has said that the Italian authorities are within their rights to reimburse Roche’s Avastin for wet AMD, even though it is not approved for that indication.
At current rates, not enough coronavirus vaccines will be manufactured in 2021 or even 2022 to meet global demand or achieve global population immunity, according to a new dataset that monitors vaccine supply agreements around the world.
Coronavirus Notebook: Africa Backs IP Waiver Proposal, CEOs To Face EU Parliamentary Hearing On Vaccine Supply
Sanofi and GSK have restarted their Phase II vaccine study, Australia is allowing public advertising of coronavirus vaccines, and Sputnik V has landed in Mexico.